COG AALL0232: Lymphoblastic Leukemia
COG AALL0232: High Risk B-Precursor Acute Lymphoblastic Leukemia
Approval Date: 12/29/2003
Principal Investigator: Charles Main, MDTo increase the cure rate of children with high- risk ALL without increasing the side effects of therapy, by determining the safety and efficacy of different drugs during the course of treatment.
Each study has its own guidelines for who can participate, called 'eligibility criteria'. Below is a partial list of criteria for acceptance into the research study. Only the study doctor can make the determination that you meet all eligibility criteria.
- Age 1-10 years: WBC >50,000
- Age > 10 years: any WBC
- Previously enrolled on AALL03B1
- Newly diagnosed B-precursor ALL
- No prior cytotoxic therapy
Status of Clinical Trial:
open and enrolling